Our Recommendations
New Publications
- Reported cases of chronic African trypanosomiasis, 2022 (2023)
- Reported cases of acute African trypanosomiasis (2024)
- New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine (2025)
- Human African Trypanosomiasis (sleeping sickness): Current knowledge and future challenges (2023)
- Human African trypanosomias: Number of new reported cases of human African trypanosomiasis (T.b. gambiense) 2023 (2023)
Filter
67
Featured
Recommendations
3
Language
Document type
Studies & Reports
22
Manuals
9
Resource Platforms
9
Brochures
6
Dashboards/Maps
6
Guidelines
5
Training Material
2
Videos
2
Strategic & Response Plan
2
Fact sheets
2
Situation Updates
1
No document type
1
Countries / Regions
Africa
7
West and Central Africa
6
East and Southern Africa
5
Global
4
Uganda
3
Congo, Democratic Republic of
2
Angola
2
South Sudan
2
Benin
1
Rwanda
1
Cameroon
1
Zimbabwe
1
Guinea
1
Middle East and North Africa
1
Southern Africa
1
Côte d’Ivoire / Ivory Coast
1
Chad
1
Authors & Publishers
Publication Years
Category
Pharmacy & Technologies
4
Public Health
2
Countries
2
Clinical Guidelines
2
Key Resources
1
WHO convened the fifth stakeholders meeting on the elimination of HAT due to infection with Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT) in Geneva, Switzerland, on 7–9 June 2023. The meeting was held again in person after the coronavirus disease (COVID-19) pandem...
Having established the goal of eliminating transmission of gambiense human African trypanosomiasis (g-HAT) to humans, the HAT-e-TAG considered which elements should be developed to assess this goal.
Database with maps and country-specific numbers
Front. Trop. Dis. , 09 May 2023 Sec. Neglected Tropical Diseases Volume 4 - 2023 | https://doi.org/10.3389/fitd.2023.1087003
The number of reported cases of chronic African trypanosomiasis (sleeping sickness). The disease is caused by parasites that are spread by tsetse flies and otherinsects. The disease is typically fatal if not treated.
Human African trypanosomiasis is caused by Trypanosoma brucei gambiense in West and Central Africa and by T. brucei rhodesiense in East Africa; both species are endemic in Uganda. Trypanosoma brucei gambiense accounts for 98% of all cases of African trypanosomiasis, and T. brucei rhodesiense account...
Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reserv...
The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was form...
Gambiense human African trypanosomiasis is a deadly infectious disease affecting West and Central Africa, South Sudan and Uganda, and transmitted between humans by tsetse flies. The disease has caused several major epidemics, the latest one in the 1990s. Thanks to recent innovations such as rapid di...
More countries eliminate human African trypanosomiasis as a public health problem: Benin and Uganda (gambiense form) and Rwanda (rhodesiense form)
Human African trypanosomiasis (HAT), or sleeping sickness, transmitted by tsetse flies in sub-Saharan Africa, is a life-threatening disease that afflict...
The main purpose of the meeting was to review tsetse control tools, activities and their contribution to the elimination of gHAT and the monitoring thereof. Seven endemic countries provided reports on recent and ongoing vector control interventions at the national level (Angola, Cameroon, Côte d’...
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...
DNDi is now striving to make fexinidazole available to the majority of people who have T.b. gambiense sleeping sickness. We are supporting a three-year access and pharmacovigilance study that began in 2020 and have so far carried out in-country training of relevant staff in 250 hospitals and...
Human African trypanosomiasis (HAT) is a lethal neglected tropical disease (NTD) transmitted by the bite of infected tsetse flies. The disease is also known as “sleeping sickness”. During the 20th century it caused enormous suffering in the endemic areas in sub-Saharan Africa. HAT transmission l...
MSD Manual Professional Version
MSD Manual Consumer Version
HAT diagnosis relies on laboratory techniques because clinical signs and symptoms are unspecific. Serodiagnostic tests exist only for Tbg and are based on the detection of specific antibodies, thus they are not confirmatory of infection. With the current low disease prevalence, the positive predicti...
HAT diagnosis relies on laboratory techniques because clinical signs and symptoms are unspecific. Serodiagnostic tests exist only for Tbg and are based on the detection of specific antibodies, thus they are not confirmatory of infection. With the current low disease prevalence, the positive predicti...
PLoS Negl Trop Dis 16(11): e0010885. https://doi.org/10.1371/journal.pntd.0010885
HAT diagnosis in non-endemic countries is rare and can be challenging, but alertness and
surveillance must be maintained to contribute to WHO’s elimination goals. Early detection is
particularly important as it co...
DNDi’s long-term goal for sleeping sickness, also known as human African trypanosomiasis (HAT), is to develop and register two new drugs that are effective against both Stage 1 and Stage 2 of the disease and both subspecies of the parasite, T.b. gambiense and T.b. rhodesiense. T.b. rhodesiense is ...
